Advertisement
Screener

IMMUNOVANT, INC. (IMVT) Price / Book

2.8 / 5 stars · 68/120 Roast Me

Immunovant, Inc. Price/Book Ratio

The price-to-book (P/B) ratio compares what the stock market says a company is worth with what the company's own books say it is worth. It is market capitalization divided by shareholder equity, the book value left after subtracting liabilities from assets, and the table shows both amounts. A ratio of 1.0 means market value equals book value; a higher ratio means investors value the company above its net assets, often for brands, software or expected growth the books do not record. A negative ratio means equity is negative. Each point uses the filed share count and the last closing price on or before the equity's reporting date, never today's price.

  • Immunovant, Inc. price/book ratio for the quarter ending 2026-06-30 was 10.82, a 140.39% increase year-over-year.
  • Immunovant, Inc. price/book ratio for the quarter ending 2026-03-31 was 5.95, a 44.70% increase year-over-year.
  • Immunovant, Inc. price/book ratio for the quarter ending 2025-12-31 was 5.24, a 49.33% decline year-over-year.
  • Immunovant, Inc. price/book ratio for the quarter ending 2025-09-30 was 5.41, a 41.82% decline year-over-year.
  • Immunovant, Inc. price/book ratio for fiscal 2026 was 10.82.
  • Immunovant, Inc. price/book ratio for fiscal 2025 was 5.24, a 49.33% decline from fiscal 2024.
  • Immunovant, Inc. price/book ratio for fiscal 2024 was 10.34, a 14.92% increase from fiscal 2023.
  • Immunovant, Inc. price/book ratio for fiscal 2023 was 9, a 62.63% increase from fiscal 2022.
Available history
2019-06-30 to 2026-06-30
Data captured

Historical Price/Book Ratio

DatePrice/Book RatioMarket capitalizationShareholder equity
2026-06-3010.82$7.95B$735.39M
2026-03-315.95$5.07B$852.59M
2025-12-315.24$5.17B$986.14M
2025-09-305.41$2.81B$519.71M
2025-06-304.5$2.74B$608.54M
2025-03-314.11$2.91B$707.45M
2024-12-3110.34$3.65B$352.62M
2024-09-309.31$4.18B$449.05M
2024-06-307.09$3.86B$544.66M
2024-03-317.61$4.7B$617.76M
2023-12-319$6.11B$679.34M
2023-09-3020.04$5.05B$251.81M
2023-06-308.26$2.48B$299.87M
2023-03-315.58$2.02B$362.49M
2022-12-315.53$2.29B$414.68M
2022-09-301.64$650.71M$395.75M
2022-06-301.04$454.44M$436.49M
2022-03-311.37$641.82M$469.83M
2021-12-311.94$980.74M$505.15M
2021-09-301.86$999.34M$536.4M
2021-06-302.83$1.04B$365.53M
2021-03-314.01$1.57B$391.48M
2020-12-3110.93$4.53B$414.15M
2020-09-307.86$3.44B$438.41M
2020-06-307.36$1.97B$267.78M
2020-03-319.04$850.71M$94.07M
2019-12-317.75$867.38M$111.86M
2019-09-30-1.52$35.4M-$23.28M
2019-06-30-2.87$34.74M-$12.11M

Annual Price/Book Ratio

DatePrice/Book RatioMarket capitalizationShareholder equity
2026-06-3010.82$7.95B$735.39M
2025-12-315.24$5.17B$986.14M
2024-12-3110.34$3.65B$352.62M
2023-12-319$6.11B$679.34M
2022-12-315.53$2.29B$414.68M
2021-12-311.94$980.74M$505.15M
2020-12-3110.93$4.53B$414.15M
2019-12-317.75$867.38M$111.86M

Similar stocks

Stock NameCountryMarket CapPE Ratio
CG Oncology, Inc. (CGON)United States$6.095B-27.95
Scholar Rock Holding Corp (SRRK)United States$5.920B-16.37
Vaxcyte, Inc. (PCVX)United States$8.466B-7.91
CRISPR Therapeutics AG (CRSP)$5.390B-11.68
ImmunityBio, Inc. (IBRX)United States$9.157B-9.29
IOVANCE BIOTHERAPEUTICS, INC. (IOVA)United States$4.897B-6.51
Adaptive Biotechnologies Corp (ADPT)United States$4.719B-53.43
Kymera Therapeutics, Inc. (KYMR)United States$9.631B-31.69
Relay Therapeutics, Inc. (RLAY)United States$3.884B-14.30
Krystal Biotech, Inc. (KRYS)United States$10.210B45.56